Oyster Point Pharma was an American biopharmaceutical company based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.[2] It was acquired by Viatris in 2023.
History
The company was founded in 2015.
In October 2021, Tyrvaya was the first nasal spray approved by Food and Drug Administration to treat dry eye syndrome.[3] This became the company's lead product.
Prior to going public, Oyster Point Pharma operated at a loss of $16.5 million in 2018.[4]
In February 2019, still at clinical stage, the company raised $93 million in its Series B funding round.[5][6]
In October 2019, the company issued 5-million shares in the initial public offering with NASDAQ Global Select Market at the price of $16 per share with the first trading day on October 31.[7] In January 2023 Viatris acquired Oyster Point Pharma in an all-cash deal.[8]
References
- SEC FORM S-1 Oyster Point Pharma, retrieved 27 April 2022^
- Oyster Point Pharma Inc Reuters, retrieved 27 April 2022^
- Laird Harrison. FDA Approves First Nasal Spray for Dry Eye WenMD Health News, 27 October 2021, retrieved 27 April 2022^
- Polina Marinova. Fair's CEO Scott Painter Resigns as Car-Leasing Startup Seeks a Path to Profitability Fortune, 31 October 2019, retrieved 27 April 2022^
- Polina Marinova. Term Sheet — Tuesday, February 26 Fortune, 26 February 2019, retrieved 27 April 2022^
- Brian Gormley. Oyster Point Pharma Banks $93 Million for Dry Eye Therapy Wall Street Journal Pro, 26 February 2019, retrieved 27 April 2022^
- Anthony Vecchione. Oyster Point Pharma shares gain in IPO NJBIZ, 31 October 2019, retrieved 27 April 2022^
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division January 3, 2023^